Roongta et al. Small RCT of MTX+LEF vs MTX+RTX in RA. 21 patients each arm. No significant difference. @RheumNow #ACR22 Abstr#0931 https://t.co/jNDrMkkvhP https://t.co/dkfUnh5SM3

• Rituximab versus Leflunomide in Combination with Methotrexate in Patients with …

Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and MTX. But more AEs when MTX without folic acid 32 vs 16% - nausea, transaminase elevations. @RheumNow #ACR22 Abstr#0930 https://t.co/jsUYG2YIZL https://t.co/YOpUbA4Ze9

• Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Rec…

IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study ◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline ◦ associated with improved BASFI, fatigue, SF36 Ramiro S Abs1009 https://t.co/GiCqg7W9IR #ACR22 @RheumNow

• Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixe…

Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dose-dependent increase in risk. Agents include quartz, asbestos, fungicides & carbon monoxide. This is a common pt question! @RheumNow ABST0601 #ACR22 https://t.co/QbsSLIXNar

• Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthri…

Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. Higher flare rate with 2 week hold. @RheumNow #ACR22 Abstr#0936 https://t.co/G53mcWFK2C https://t.co/VFY9TS5OIv

• Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on…

Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs P Mease on BE MOBILE 1 & 2 BKZ 160 mg q4w vs PBO 254 pts w nr-axSpA, 332 w AS Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16 @RheumNow https://t.co/nxZFSrb2XK

Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA 31 CBTT courses in 29 SpA pts - 69% also w IBD Most common: TNF+IL12/23 or IL17 12 pts (38%) d/c CBTT - 7 inefficacy (5 2/2 IBD), 2 for AEs, 3 for other causes. 2 serious AEs (pulm infiltrates, staph ifn) @RheumNow https://t.co/zExkpam0zK

Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease. No significant difference. But 59% vs 32% for irAEs and 23% vs 10% for high grade irAEs @RheumNow #ACR22 Abstr#0757 https://t.co/UYhRM4xO9r https://t.co/r4NurxXzGZ

• Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Sin…

Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All forms progesterone appears equally safe (differs ACR guidance which does not recommended IM or implant) @RheumNow #ACR22 Abstr#0943 https://t.co/HGuZJgaRZQ https://t.co/KrIaKaYNTy

• Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positiv…

7pm ET on 11/13, join our SLE panel. #ACR22 https://t.co/B8XdaJFLS2 https://t.co/kqJRI2QRms

• https://bit.ly/3tuxpH6

It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials. A compelling bench-to-bedside story by @MdWarrington, Dr. Weyand, Dr. Koster and team, and definitely a space to watch #ACR22 @RheumNow https://t.co/2acKFrWOUF

"You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis" -John Stone #ACR22 @RheumNow

LILAC study abstracts 0364 and 0365 SLE pts w/ joint and skin activity treated with BIIB059 had consistent improvements vs PBO. More to come! #ACR22 @RheumNow https://t.co/WPl3tol7v9 and https://t.co/8cyrI3W9rD https://t.co/5W4KMOHHEA

• Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Syste…
• Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participa…

Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest ⁦@RheumNow⁩ #ClinicalPearl https://t.co/S8fHi7dFoD